Across TCGA pan-cancer cohorts, HAPLN4 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated HAPLN4 data layer compared with 11 for mass-spec protein.
The strongest signal is observed in small cell lung cancer (SCLC), where higher HAPLN4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HAPLN4 expression acts as an unfavorable survival marker.
SCLC, OV, and KICH are the cancer types where HAPLN4 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.